Navigation Links
Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
Date:9/29/2009

NATICK, Mass., Sept. 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the Palmaz-NIR suit. All the disputes involved intellectual property in the interventional cardiology arena. In connection with the settlement, Boston Scientific will make a payment of $716 million to Johnson & Johnson. The settlement payment is within Boston Scientific's existing reserve for the Palmaz-NIR suit and will be made from existing cash on hand.

"We are pleased we have been able to significantly reduce the amount of outstanding litigation we have with Johnson & Johnson," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "We continue to work with them to resolve other outstanding matters."

The settlement includes cross licenses for all the patents in the suits, other than the Palmaz patent, which has expired.

The lawsuits are listed below.

  1. Cordis Corporation v. Medtronic Vascular, Inc., Boston Scientific Corporation et al., D. Del., CA 97-550;
  2. Johnson & Johnson Inc., Expandable Grafts Partnership & Cordis Corporation v. Boston Scientific Ltd./Boston Scientifique LTEE, Canadian Federal Court, Toronto, Ontario docket: T-1822-97;
  3. Johnson & Johnson Inc. v. Boston Scientific Ltd./Boston Scientifique LTEE, Canadian Federal Court, Toronto, Ontario docket T-63-08;
  4. Boston Scientific Corporation v. Johnson & Johnson, ND Cal., CA 3:02-cv-790;
  5. Schneider (Europe) GmbH v. Johnson & Johnson Medical NV, Brussels Court of First Instance under General Docket No. A.R. 04/9656/A/;
  6. Schneider (Europe) GmbH v. Cordis Medizinische Apparate GmbH, Dusseldorf District Court, Action No. 4b O 211/07;
  7. Schneider (Europe) GmbH v. Cordis, First Instance Court of Paris, Docket No. 06/02.924;
  8. Schneider (Europe) GmbH v. Johnson & Johnson Medical S.P.A., Court of Turin;
  9. Cordis v. Schneider - Damage request filed August 3, 2009;
  10. Boston Scientific Scimed, Inc. v. Cordis Corporation, D. Del., CA 03-283;
  11. Boston Scientific Scimed Inc. v. Cordis Medizinische Apparate GmbH, District Court of Mannheim, Civil Division, docket No. 7 O 429/04;
  12. Boston Scientific Scimed Inc. v. Cordis Medizinische Apparate GmbH, District Court of Mannheim, Civil Division, docket No. 7 O 18/08;
  13. Scimed Life Systems, Inc. v. Cordis Corporation, United States District Court, Minnesota, Civil Action 97-752; and
  14. Cordis Corporation v. Scimed Life Systems, Inc., United States District Court, Minnesota, Civil Action 4-96-261.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding litigation, intellectual property and new product development. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation

SOURCE Boston Scientific Corporation


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
2. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
3. Boston Scientific Announces Schedule for European Society of Cardiology Congress
4. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
5. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
6. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
7. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
8. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
9. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
10. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
11. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017  Genesis ... HME Company. The announcement was made by Bill ... David Hartley and Nathan Feltman , ... of Genesis Healthcare Services, LLC. This ... nation,s largest provider of technology enabled durable medical equipment ...
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Fibromyalgia ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... Thinksport, the most award-winning sunscreen on the ... Marin. For the second year in a row, cyclists will stay protected from ... thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts again ...
(Date:2/23/2017)... ... 2017 , ... Rare Disease Report®, which is the only ... Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on February ... e-newsletter and quarterly publication, will be conducting interviews with patients and advocates in ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... Denver, Colorado (PRWEB) , ... February 23, 2017 ... ... Dialog Magazine, an exciting, new, interactive publication where generations converge and explore the ... to expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, ...
(Date:2/23/2017)... ... 23, 2017 , ... The Center for Autism and Related ... Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The ... see films in an environment that accommodates their unique needs. , Launched in ...
Breaking Medicine News(10 mins):